|
Population size
|
0-2
|
63,025
|
2006 Census [42]
|
| |
3-4
|
42,260
| |
| |
5-17
|
322,670
| |
| |
18-24
|
203,500
| |
| |
25-54
|
975,875
| |
| |
55-64
|
237,795
| |
| |
≥65
|
271,455
| |
| |
Total
|
2,116,580
| |
|
Latent period (days)
|
All
|
3 (2-4)
|
Tuite et al. 2010 [22]
|
|
Initial asymptomatic infectious period (in all infected individuals) (days)
|
All
|
1
|
Liao et al. 2010 [43]
|
|
Total duration of infectiousness (days)
|
All
|
7 (5-7)
|
Tuite et al. 2010 [22]; De Serres [44]
|
|
Basic Reproduction number (R
0)
|
All
|
1.4 (1.2-1.8)
|
Pourbohloul et al. 2009 [27]
|
|
Proportion of population with pre-existing immunity
|
≥55
|
0.5
|
Centers for Disease Control and Prevention 2009 [13]; Fisman et al. 2009 [6]
|
|
Vaccine efficacy
|
All
|
0.9 (0.5-1)
|
Product Monograph Arepanrix(tm) H1N1 [45]; Waddington et al., 2010 [46]
|
|
Proportion of infected individuals who self-isolate
|
All
|
0.1 (0.1-0.6)
|
Assumption
|
|
Mortality (per 100,000 infections)
|
0-2
|
30
|
Donaldson et al. 2009 [47]
|
| |
2-4
|
27
| |
| |
5-17
|
11
| |
| |
18-24
|
12
| |
| |
25-54
|
30
| |
| |
55-64
|
65
| |
| |
≥65
|
980
| |
